MedTrace Logo

Observation of Treatment With Certolizumab Pegol in Daily Practice

NCT01069419 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1117

Last updated 2015-10-29

Study results available
· View outcomes & findings →

Summary

This is an observational, non-interventional, non-comparative, post-authorization safety study to evaluate efficacy and long-term safety of Cimzia in adult patients with RA in need of treatment with a biological product.

Conditions

Sponsors & Collaborators

  • UCB Pharma GmbH

    lead INDUSTRY

Principal Investigators

  • UCB Clinical Trial Call center · +1 877 822 9493 (UCB)

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2014-09-30
Completion
2014-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01069419 on ClinicalTrials.gov